Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. The biotech said the changes reflect the comorbidities of people with acute on-chronic liver failure (ACLF) and the logistics of caring for the patients.
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of confirmed disability progression. The drugmaker plans to seek approval this year.
The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.
After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh deal announcement of the year so far.
Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going.
Masimo’s long-running proxy fight has come to a close, at least for now. During the company’s annual meeting, shareholders elected two board members nominated by activist investor Politan Capital Management—and ousted the medtech’s founder and CEO, Joe Kiani, in the process.
Stocks fell on Wall Street as a strong year for the market looks set to end on a sour note
Federal officials say the United States saw an 18.1% increase in homelessness, a dramatic rise driven mostly by a lack of affordable housing as well as devastating natural disasters and a surge of migrants in several parts of the country
Stocks are closing lower as Wall Street ends a holiday-shortened week on a down note
U.S. stocks ended sharply lower on Monday as some traders took profits before the end of the year, dimming hopes for the “Santa Claus rally.”
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Jasper dials up dose after complete responses come and go quickly in hives trial
Novartis channels Gargamel, terminating midphase SMURF1 trial
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
